Japan’s recent Upper House election delivered a stinging defeat for the ruling Liberal Democratic Party (LDP) and junior coalition partner…
BUSINESS
Gilead Japan Eyes High-Single-Digit Annual Growth with Oncology as Third Biz Pillar
Gilead Sciences is looking to achieve high-single-digit annual revenue growth in Japan, Kennet Brysting, who took the local helm of the company in January, tells Jiho. The drug maker is set to expand its Japan organization as it gears up…
To read the full story
Related Article
BUSINESS
- Takeda Sees Limited Tariff Exposure as US Remains Strategic Priority
July 31, 2025
- Astellas Assembles Task Team to Assess US Tariff Risks
July 31, 2025
- Kissei Licenses Thyroid Eye Disease Candidates from Viridian
July 31, 2025
- Novo Japan Files Sogroya for SGA-Related and Noonan Syndrome Short Stature
July 31, 2025
- AstraZeneca, Japanese Circulation Association Join Hands to Tackle Cardiovascular Disease
July 31, 2025
A recent conversation with a US biopharma senior director highlighted a critical talent gap: a strong demand for individuals with strategic management, critical thinking, and advanced business acumen-skills beyond traditional operational excellence. After the conversation, I rushed home and picked…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…